OTC nicotine patch trials fall short of Waxman/Hatch requirements -- petition.
This article was originally published in The Tan Sheet
Executive Summary
OTC HABITROL WAXMAN/HATCH MARKET EXCLUSIVITY CHALLENGED in a Feb. 24 citizen petition submitted on behalf of an unnamed client by D.C. attorney Jur Strobos, MD (Greenberg Traurig Hoffman Lipoff Rosen & Quentel). The petition requests that FDA deny three years of marketing exclusivity to OTC Habitrol, if approved, and maintains, more broadly, that the agency should not allow three years of marketing exclusivity for any OTC nicotine patch because clinical trials on such products do not meet the statutory requirements for exclusivity.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning